Stock price quadrupled in 3 years, market value surpasses leading Illumina! This "cancer early screening" company is highly favored by Wall Street.

```

A company specializing in cancer recurrence detection is reshaping the landscape of the blood tumor testing market.

Headquartered in Austin, Texas, Natera has achieved a near-monopoly in the field of minimal residual disease (MRD) detection. Its stock price has quadrupled in three years, reaching a market capitalization of about $31 billion, surpassing gene sequencing giant Illumina. The company’s revenue jumped from around $1 billion in 2023 to $2.3 billion last year, and analysts expect it to further rise to $2.77 billion this year.

However, the impressive growth trajectory has also brought valuation pressure. Despite Natera's first-quarter revenue rising 39% year-on-year to $697 million, beating market expectations, its stock fell about 10% last week. With a high valuation of 10 to 11 times forward revenue, any growth data short of perfection can make the market nervous.

Wall Street’s long-term bullish logic remains clear: The penetration rate of MRD testing is currently only about 6%. Leerink Partners analyst Puneet Souda estimates the domestic market size at $20 billion, and the growth potential is far from being released. Whether Natera can extend its business from academic hospitals to community oncologists and replicate its success internationally will be key to maintaining strong growth.

MRD Testing: A More Certain Business Than “Early Screening”

Public attention to cancer blood tests has long focused on early screening products for multiple cancers, such as Grail’s Galleri—which promises to screen for over 50 cancers with a single blood draw, garnering extensive media coverage and even Super Bowl advertisements.

But for investors, more certain opportunities actually come from a less glamorous field: Cancer recurrence detection.

For patients who have just undergone tumor removal surgery, the most critical question is: Has every cancer cell been completely cleared? Many oncologists now use blood tests to answer this question, offering results months earlier than traditional imaging scans.

The core problem with early screening for multiple cancers is insufficient sensitivity—especially low detection rates for early-stage cancers such as breast and prostate cancer. MRD testing is completely different: Since the starting point is the DNA of the original tumor, it can precisely target the objective, acting as a “sniper” rather than casting a “wide net.”

City of Hope oncologist Neel Talwar says: "When a tumor appears in imaging, it's often too late. Chemotherapy is far more effective at clearing micro-lesions than the macroscopic lesions visible in scans."

Signatera: Personalized Testing Builds Technical Moat

Natera’s flagship product Signatera employs a “tumor-informed” technical pathway. After tumor removal, Natera sequences the tumor tissue, identifies its unique genetic characteristics, and then customizes a personalized blood test to track whether the same mutations exist in subsequent blood samples.

This technical pathway has given Signatera an almost monopoly position in the MRD market. However, large-scale adoption still faces practical obstacles: Commercial insurance companies currently only pay for related tests in about 25% of cases, covering about half of eligible patient groups, notes TD Cowen analyst Dan Brennan. Medicare has included such tests in its reimbursement range, but broader coverage by commercial insurers will depend on clinical trials proving that interventions based on blood test results can actually extend patient survival, thus prompting organizations such as the National Comprehensive Cancer Network (NCCN) to update treatment guidelines.

Currently, Natera has submitted an application to the U.S. Food and Drug Administration (FDA) for Signatera’s use in bladder cancer indications, supported by late-stage clinical trial data showing improved patient survival. Brennan says broader market breakthroughs will depend on trial results for bigger cancer types and subsequent updates to guidelines.

The Japanese Market May Be a Near-term Catalyst

In the international market, a potential near-term catalyst is taking shape. Natera expects to gain regulatory approval in Japan for colorectal cancer indications as early as this quarter.

Unlike the fragmented insurance system in the U.S., Japan implements a single national health insurance system. Once approved, Signatera will likely gain access nationwide, opening up the market far more efficiently than in the U.S.

Natera CEO Steve Chapman envisions a grander plan: Every cancer survivor undergoes genetic sequencing at the time of diagnosis and receives a blood test every few months thereafter.

But this market will not remain Natera’s alone for long. Guardant Health is currently its closest competitor, while Tempus AI and Roche present longer-term competitive threats. Natera’s acquisition of Foresight Diagnostics last year is seen as a strategic move to consolidate its technological lead.

Risk Warning and DisclaimerThe market carries risks, and investments require caution. This article does not constitute personal investment advice, nor does it take into account the unique investment goals, financial circumstances, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article suit their own situation. Investments based on this article are at your own risk. ```